

TOTAL SYNTHESIS OF ANTIOXIDANT ALKALOID CARAZOSTATIN VIA ELECTROCYCLIC RING CLOSURE OF 3-BUTADIENYL-2-METHOXYINDOLE


Yoshinori Nonaka,*¹ Tomomi Kawasaki,² and Masanori Sakamoto*²

¹ Kissei Pharmaceutical Co., LTD., 4365-1 Kashiwabara, Hotaka,
Minamiazumi, Nagano 399-8304, Japan

² Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-
8588, Japan

Abstract – Total synthesis of the naturally occurring antioxidant carazostatin was accomplished by an efficient method, Wittig reaction of 2-methoxyindol-3-one followed by electrocyclic reaction of 3-(1,3-butadienyl)indole.


Antioxidants are served as possible protective agents against a variety of diseases induced by oxygen-derived free radicals, like myocardial and cerebral ischemia, arteriosclerosis, inflammation, rheumatism, senility, autoimmune diseases, and cancer.¹ Recently, as a novel class of antioxidant active compounds, several poly-substituted 3-hydroxycarbazole alkaloids were isolated from *Streptomyces*.² Because of their potent antioxidative activities and unique structures, the interest of many synthetic chemists was attracted in developing novel synthetic methodologies for these alkaloids and their related compounds.³ The representative 3-hydroxycarbazole, carazostatin (**1**) exhibits an antioxidant activity more effective than α -tocopherol.^{2a} The total syntheses of carazostatin (**1**) were accomplished by some methodologies using the Diels-Alder reaction,^{4a} iron-mediated oxidative cyclization,^{4b} unique



Scheme 1

aromatic annulation,^{4c} and electrocyclicization of the allene intermediate.^{4d} We earlier reported a synthetic method for poly-substituted 3-methoxycarbazole alkaloids, hyellazole and 4-deoxycarbazomycin B.⁵ In this communication, we describe a novel synthesis of carazostatin (**1**) utilizing the thermal electrocyclic ring closure of 1-(2-methoxyindol-3-yl)-2-oxybutadiene as shown in Scheme 1.

The starting material 2-methoxyindol-3-one (**2**) was readily available by our previously described method.⁶ The phosphonium ylide (**3**) was prepared as follows: Wittig reaction of octyl aldehyde (**4**) with the ylide (**5**) gave (*E*)- α,β -unsaturated ester (**6**) in quantitative yield with high stereoselectivity. After hydrolysis of the α,β -unsaturated ester (**6**) with LiOH, the carboxylic acid (**7**) was converted to α,β -unsaturated acid chloride (**8**) by treatment with thionyl chloride. The resulting acid chloride (**8**) was allowed to react with 2 equiv. of methyldiene phosphorane (**9**) at 0 °C affording the desired ylide (**3**) in good yield.



The reaction of 2-methoxyindol-3-one (**2**) with the ylide (**3**) in refluxing toluene took place smoothly with Wittig reaction followed by isomerization to afford the 3-substituted indole (**10**) in 72% yield. The resulting indole (**10**) was treated with trimethylsilyl iodide (TMSI) in the presence of 1,1,1,3,3,3-hexamethyldisilazane (HMDS) to give stereoselectively (*Z*)-enolate (**11**) in 75% yield. The stereochemistry of TMS-enolate (**11**) was confirmed by nuclear Overhauser effect (NOE) experiments; irradiation of methyl proton enhanced the signals of the olefinic and methylene protons as shown in Scheme 3. When the enolate (**11**) was heated in boiling decalin, isomerization, cyclization, and elimination of methanol occurred to give the desired 3-siloxycarbazole (**12**) in moderate yield. The desilylation of **12** was performed by treatment with tetrabutylammonium fluoride (TBAF) to afford 3-hydroxycarbazole (**13**) in 49% yield. The deacetylation of 3-hydroxycarbazole (**13**) by the usual hydrolysis method was unsuccessful, however, the reductive deacetylation of **13** with lithium aluminum hydride at 0 °C provided

- Acad. Sci. U.S.A.*, 1989, **86**, 4695. (e) P. A. Cerutti, *Science*, 1985, **227**, 375.
2. (a) Carazostatin for the isolation: S. Kato, H. Kawai, T. Kawasaki, Y. Toda, T. Urata, and Y. Hayakawa, *J. Antibiot.*, 1989, **42**, 1879. For its bioactivity: M. Iwatsuki, E. Niki, S. Kato, and K. Nishikori, *Chem. Lett.*, 1992, 1735; S. Kato, T. Kawasaki, T. Urata, and J. Mochizuki, *J. Antibiot.*, 1993, **46**, 1859; M. Iwatsuki, E. Niki, and S. Kato, *BioFactors*, 1993, **4**, 123. (b) Carabazomadurins: N. Kotoda, K. Shin-ya, K. Furihata, Y. Hayakawa, and H. Seto, *J. Antibiot.*, 1997, **50**, 770. (c) Antiostatins: C. J. Mo, K. Shin-ya, K. Furihata, K. Furihata, S. Shimazu, Y. Hayakawa, and H. Seto, *J. Antibiot.*, 1990, **43**, 1337. (d) Neocarbazostatins: S. Kato, K. Shindo, Y. Kataoka, Y. Yamagishi, and J. Mochizuki, *J. Antibiot.*, 1991, **44**, 903.
3. For recent reviews: (a) U. Pindur, *Chimia*, 1990, **44**, 406. (b) J. Bergman and B. Pelcman, *Pure Appl. Chem.*, 1990, **62**, 1967. (c) H.-J. Knölker, *Synlett*, 1992, 371. (d) T. Kawasaki and M. Sakamoto, *J. Indian Chem. Soc.*, 1994, **71**, 443. (e) C. J. Moody, *Synlett*, 1994, 681. (f) H.-J. Knölker, 'Advances in Nitrogen Heterocycles', Vol. 1, ed. by C. J. Moody, JAI Press: Greenwich, CT(USA), 1995, p. 173. (g) S. Hibino and E. Sugino, 'Advances in Nitrogen Heterocycles', Vol. 1, ed. by C. J. Moody, JAI Press: Greenwich, CT(USA), 1995, p. 205.
4. For the previous syntheses of carazostatin : (a) P. M. Jackson and C. J. Moody, *Synlett*, 1990, 521. P. M. Jackson, C. J. Moody, and R. J. Mortimer, *J. Chem. Soc., Perkin Trans. 1*, 1991, 2941. (b) H. J. Knölker and T. Hopfman, *Synlett*, 1995, 981. (c) K. Shin and K. Ogasawara, *Chem. Lett.*, 1995, 289. (d) T. Choshi, T. Sada, H. Fujimoto, C. Nagayama, E. Sugino, and S. Hibino, *Tetrahedron Lett.*, 1996, **37**, 2593; T. Choshi, T. Sada, H. Fujimoto, C. Nagayama, E. Sugino, and S. Hibino, *J. Org. Chem.*, 1997, **62**, 2535.
5. (a) T. Kawasaki, Y. Nonaka, and M. Sakamoto, *J. Chem. Soc., Chem. Commun.*, 1989, 43. (b) T. Kawasaki, Y. Nonaka, M. Akahane, N. Maeda, and M. Sakamoto, *J. Chem. Soc., Perkin Trans. 1*, 1993, 1777.
6. C. Chien, T. Suzuki, T. Kawasaki, and M. Sakamoto, *Chem. Pharm. Bull.*, 1984, **32**, 3945.
7. Carazostatin (**1**): mp 157.5-159 °C (from ether-hexane), (lit., mp 149-152 °C^{2a}; 159-160 °C^{4d}). ¹H-NMR (400 MHz, CDCl₃) δ: 0.89 (3H, t, *J* = 7 Hz), 1.20-1.50 (8H, m), 1.60-1.70 (2H, m), 2.37 (3H, s), 2.88 (2H, t, *J* = 8 Hz), 4.58 (1H, br s), 7.16 (1H, t, *J* = 8 Hz), 7.32-7.46 (3H, m), 7.75 (1H, br s), 7.93 (1H, d, *J* = 8 Hz). ¹³C-NMR (100 MHz, CDCl₃) δ: 12.2, 14.4, 22.9, 29.1, 29.6, 29.8, 30.3, 32.2, 103.2, 110.9, 119.2, 120.3, 121.1, 121.6, 123.9, 124.4, 125.5, 134.2, 140.0, 148.4.